Last reviewed · How we verify

Lupin Ltd. — Portfolio Competitive Intelligence Brief

Lupin Ltd. pipeline: 3 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE marketed Other
Lupin's Pegfilgrastim Lupin's Pegfilgrastim marketed
ARMLUPEG PEGFILGRASTIM-UNNE marketed Leukocyte Growth Factor [EPC] Other
Oral Capsule Mexiletine (IR) Oral Capsule Mexiletine (IR) phase 3 Class IB antiarrhythmic agent Cardiac voltage-gated sodium channel (Nav1.5) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Berlex Labs · 1 shared drug class
  4. EVIVE BIOTECHNOLOGY · 1 shared drug class
  5. FRESENIUS KABI USA · 1 shared drug class
  6. KASHIV BIOSCIENCES LLC · 1 shared drug class
  7. MYLAN GMBH · 1 shared drug class
  8. SANDOZ INC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lupin Ltd.:

Cite this brief

Drug Landscape (2026). Lupin Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lupin-ltd. Accessed 2026-05-15.

Related